The retinoid X receptor agonist bexarotene (Targretin) synergistically enhances the growth inhibitory activity of cytotoxic drugs in non-small cell lung cancer cells

Lung Cancer

Volumn 50, Issue 1, 2005, Pages 9-18

  Hermann, Thomas W ^a   Yen, Wan Ching ^a   Tooker, Patricia ^a   Fan, Bingqi ^a   Roegner, Karen ^a   Negro Vilar, Andrés ^a   Lamph, William W ^a   Bissonnette, Reid P ^a  

^a LIGAND PHARMACEUTICALS INC   (United States)

Author keywords

Bexarotene; Drug synergy; Non small cell lung cancer; Retinoid X receptor; Targretin

Indexed keywords

BEXAROTENE; CYTOTOXIC AGENT; NAVELBINE; PACLITAXEL; RETINOID X RECEPTOR;

AGONIST; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER MODEL; CANCER PATIENT; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; DRUG SCREENING; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; LUNG NON SMALL CELL CANCER; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PLASMA; PRIORITY JOURNAL; STANDARD; TUMOR MODEL; TUMOR XENOGRAFT;

ANIMALS; ANTICARCINOGENIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG INTERACTIONS; HUMANS; LUNG NEOPLASMS; MALE; MICE; MICE, NUDE; PACLITAXEL; TETRAHYDRONAPHTHALENES; TRANSPLANTATION, HETEROLOGOUS; VINBLASTINE;

EID: 24744435139     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2005.05.008     Document Type: Article

References (39)

1. A. Jemal, R.C. Tiwari, T. Murray, A. Ghafoor, A. Samuels, and E. Ward Cancer statistics, 2004 CA Cancer J Clin 54 2004 8 29
2. H. Cortes-Funes New treatment approaches for lung cancer and impact on survival Semin Oncol 29 2002 26 29
3. A. Spira, and D.S. Ettinger Multidisciplinary management of lung cancer N Engl J Med 350 2004 379 392
4. K. Kelly, N. Mikhaeel-Kamel, Z. Pan, J. Murphy, S. Prindiville, and P.A. Bunn Jr. A phase I/II trial of paclitaxel, carboplatin, and gemcitabine in untreated patients with advanced non-small cell lung cancer Clin Cancer Res 6 2000 3474 3479
5. G. Frasci, N. Panza, P. Comella, G.P. Nicolella, M. Natale, and L. Manzione Cisplatin, gemcitabine, and paclitaxel in locally advanced or metastatic non-small-cell lung cancer: a phase I-II study. Southern Italy Cooperative Oncology Group J Clin Oncol 17 1999 2316 2325
6. R.S. Herbst, G. Giaccone, J.H. Schiller, R.B. Natale, V. Miller, and C. Manegold Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2 J Clin Oncol 22 2004 785 794 [see comment]
7. G. Giaccone, R.S. Herbst, C. Manegold, G. Scagliotti, R. Rosell, and V. Miller Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1 J Clin Oncol 22 2004 777 784
8. R. Perez-Soler The role of erlotinib (Tarceva, OSI 774) in the treatment of non-small cell lung cancer Clin Cancer Res 10 2004 4238s 4240s
9. M.F. Boehm, L. Zhang, B.A. Badea, S.K. White, D.E. Mais, and E. Berger Synthesis and structure-activity relationships of novel retinoid X receptor-selective retinoids J Med Chem 37 1994 2930 2941
10. M.M. Gottardis, E.D. Bischoff, M.A. Shirley, M.A. Wagoner, W.W. Lamph, and R.A. Heyman Chemoprevention of mammary carcinoma by LGD1069 (Targretin): an RXR-selective ligand Cancer Res 56 1996 5566 5570
11. E.D. Bischoff, R.A. Heyman, and W.W. Lamph Effect of the retinoid X receptor-selective ligand LGD1069 on mammary carcinoma after tamoxifen failure J Natl Cancer Inst 91 1999 2118
12. E.D. Bischoff, M.M. Gottardis, T.E. Moon, R.A. Heyman, and W.W. Lamph Beyond tamoxifen: the retinoid X receptor-selective ligand LGD1069 (TARGRETIN) causes complete regression of mammary carcinoma Cancer Res 58 1998 479 484
13. W-C. Yen, R.Y. Prudente, and W.W. Lamph Synergistic effect of a retinoid X receptor-selective ligand bexarotene (LGD1069, Targretin) and paclitaxel (Taxol) in mammary carcinoma Breast Cancer Res Treat 88 2004 141 148
14. W-C. Yen, M.R. Corpuz, R.Y. Prudente, T.A. Cooke, R.P. Bissonnette, and A. Negro-Vilar A selective retinoid X receptor agonist LGD1069 (Targretin) prevents and overcomes acquired paclitaxel (Taxol) resistance in human non-small-cell lung cancer (NSCLC) Clin Cancer Res 10 2004 8656 8664
15. T.C. Chou, and P. Talalay Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors Adv Enzyme Regul 22 1984 27 55
16. T.-C. Chou The median-effect principle and the combination index for quantitation of synergism and antagonism T.-C. Chou D.C. Rideout Synergism and Antagonism in Chemotherapy 1991 Academic Press New York, NY 61 102
17. S.B. Horwitz, D. Cohen, S. Rao, I. Ringel, H.J. Shen, and C.P. Yang Taxol: mechanisms of action and resistance J Natl Cancer Inst Monogr 15 1993 55 61
18. M.A. Jordan, D. Thrower, and L. Wilson Mechanism of inhibition of cell proliferation by Vinca alkaloids Cancer Res 51 1991 2212 2222
19. C. Etievant, A. Kruczynski, O. Pauwels, and R. Kiss The combination of the tetrazolium derivative reduction (MTT) and digital cell image analysis to monitor in vitro the cytotoxicity of anti-neoplastic drugs Anticancer Res 11 1991 305 311
20. P.B. Schiff, and S.B. Horwitz Taxol stabilizes microtubules in mouse fibroblast cells Proc Natl Acad Sci USA 77 1980 1561 1565
21. M.V. Blagosklonny, P. Giannakakou, W.S. El-Deiry, D.G. Kingston, P.I. Higgs, and L. Neckers Raf-1/bcl-2 phosphorylation: a step from microtubule damage to cell death Cancer Res 57 1997 130 135
22. M.V. Blagosklonny, T. Schulte, P. Nguyen, J. Trepel, and L.M. Neckers Taxol-induced apoptosis and phosphorylation of Bcl-2 protein involves c-Raf-1 and represents a novel c-Raf-1 signal transduction pathway Cancer Res 56 1996 1851 1854
23. R.K. Srivastava, Q.S. Mi, J.M. Hardwick, and D.L. Longo Deletion of the loop region of Bcl-2 completely blocks paclitaxel-induced apoptosis Proc Natl Acad Sci USA 96 1999 3775 3780
24. C. Han, A.J. Demetris, G.K. Michalopoulos, Q. Zhan, J.H. Shelhamer, and T. Wu PPARgamma ligands inhibit cholangiocarcinoma cell growth through p53-dependent GADD45 and p21 pathway Hepatology 38 2003 167 177
25. 3 in ovarian cancer cells mediated through the induction of GADD45 via an exonic enhancer J Biol Chem 278 2003 48030 48040
26. L. Fajas, V. Egler, R. Reiter, S. Miard, A.M. Lefebvre, and J. Auwerx PPARgamma controls cell proliferation and apoptosis in an RB-dependent manner Oncogene 22 2003 4186 4193
27. L.F. Lee, G. Li, D.J. Templeton, and J.P. Ting Paclitaxel (Taxol)-induced gene expression and cell death are both mediated by the activation of c-Jun NH2-terminal kinase (JNK/SAPK) J Biol Chem 273 1998 28253 28260
28. H.L. Pahl Activators and target genes of Rel/NF-kappaB transcription factors Oncogene 18 1999 6853 6866
29. V. Vivat-Hannah, D. You, C. Rizzo, J.P. Daris, P. Lapointe, and F.C. Zusi Synergistic cytotoxicity exhibited by combination treatment of selective retinoid ligands with taxol (Paclitaxel) Cancer Res 61 2001 8703 8711
30. A. Arlt, and H. Schafer NFkappaB-dependent chemoresistance in solid tumors Int J Clin Pharmacol Ther 40 2002 336 347
31. L. Yang, H.T. Kim, D. Munoz-Medellin, P. Reddy, and P.H. Brown Induction of retinoid resistance in breast cancer cells by overexpression of cJun Cancer Res 57 1997 4652 4661
32. T.K. Chen, L.M. Smith, D.K. Gebhardt, M.J. Birrer, and P.H. Brown Activation and inhibition of the AP-1 complex in human breast cancer cells Mol Carcinog 15 1996 215 226
33. D.R. Jones, R.M. Broad, L.D. Comeau, S.J. Parsons, and M.W. Mayo Inhibition of nuclear factor kappaB chemosensitizes non-small cell lung cancer through cytochrome c release and caspase activation J Thorac Cardiovasc Surg 123 2002 310 317
34. M.H. Rendi, N. Suh, W.W. Lamph, S. Krajewski, J.C. Reed, and R.A. Heyman The selective estrogen receptor modulator arzoxifene and the rexinoid LG100268 cooperate to promote transforming growth factor beta-dependent apoptosis in breast cancer Cancer Res 64 2004 3566 3571
35. K.H. Dragnev, I. Pitha-Rowe, Y. Ma, W.J. Petty, D. Sekula, and B. Murphy Specific chemopreventive agents trigger proteasomal degradation of G1 cyclins: implications for combination therapy Clin Cancer Res 10 2004 2570 2577
36. J.W. Harbour, R.X. Luo, A. Dei Santi, A.A. Postigo, and D.C. Dean Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1 Cell 98 1999 859 869
37. A.S. Lundberg, and R.A. Weinberg Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin-cdk complexes Mol Cell Biol 18 1998 753 761
38. M.P. Markey, S.P. Angus, M.W. Strobeck, S.L. Williams, R.W. Gunawardena, and B.J. Aronow Unbiased analysis of RB-mediated transcriptional repression identifies novel targets and distinctions from E2F action Cancer Res 62 2002 6587 6597
39. J. Brabender, K.D. Danenberg, R. Metzger, P.M. Schneider, R.V. Lord, and S. Groshen The role of retinoid X receptor messenger RNA expression in curatively resected non-small cell lung cancer Clin Cancer Res 8 2002 438 443